Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giuseppe Giannini has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A mixture of postbiotics/tyndallized probiotics reduces trimethylamine (TMA) in trimethylaminuria models: Evidence from in vitro and in vivo studies

    by Giuseppe Giannini, Sara Soldi, Marina Elli, Valeria Sagheddu, Andrea Castagnetti, Elisa Viciani, Laura Salvini, Gianfranco Battistuzzi, Ferdinando Maria Milazzo, Simona Alibrandi, et al.

    Introduction: Trimethylaminuria (TMAU), also known as “fish-odor syndrome,” is a rare metabolic disorder characterized by a body malodor that smells like a decaying fish. This syndrome is caused by a FMO3 liver enzyme malfunction, leading to trimethylamine (TMA) accumulation. To date, there is no definitive therapeutic treatment but only palliative care for TMAU, such as a controlled diet, taking antibiotics, or using acidic soaps to capture sweat-released TMA.Methods: Here, we describe an innovative approach for the treatment of this disorder, where the use of postbiotics/tyndallized probiotics is able to effectively inhibit the bacterial TMA lyase present, thus preventing the formation of TMA. We obtained a preparation (a mixture of tyndallized probiotics and their postbiotics) that was derived from the fermentation of Lacticaseibacillus paracasei in the presence of garlic extract and senna leaf. This preparation was used in in vitro assays on human fecal slurry while monitoring the levels of TMA released over time, and it was also tested in vivo in both Mus musculus C57BL/6 (FMO3+/+) strain WT and C57BL/6-Fmo3em1Smoc (KO) mouse models to measure the trimethylamine N-oxide (TMAO) and TMA levels in the blood and urine, along with gut microbiota analysis in feces via next-generation sequencing (NGS).Results: L. paracasei fermentation yielded 4.1 × 1012 CFU/g lyophilized powder. In vitro assays involving fecal slurries supplemented with the fermentation product demonstrated a reduction in TMA levels, and the NGS analysis revealed that Collinsella, Clostridium, and Streptococcus were the most common bacterial genera that produced TMA. The in vivo study showed a significant reduction in TMAO levels in C57BL/6(FMO3+/+) strain WT mouse models and in TMA levels in C57BL/6-Fmo3em1Smoc (KO) mouse models. In addition, bacteria belonging to the TMA-producing genera were still present after treatment with the tested compounds, excluding their bactericidal action. The postbiotics obtained may find a useful therapeutic application both in the prevention of cardiovascular events and as valid supports to reduce TMA production in TMAU patients.


  • Open Access

    Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies

    by Antonina Sidoti, Rosalia D’angelo, Andrea Castagnetti, Elisa Viciani, Concetta Scimone, Simona Alibrandi, Giuseppe Giannini

    Trimethylaminuria (TMAU) is a rare metabolic syndrome caused by the accumulation of trimethylamine in the body, causing odor emissions similar to rotten fish in affected patients. This condition is determined by both genetic and environmental factors, especially gut dysbiosis. The multifactorial nature of this syndrome makes for a complex and multi-level diagnosis. To date, many aspects of this disease are still unclear. Recent research revealed the FMO3 haplotypes’ role on the enzyme’s catalytic activity. This could explain why patients showing only combined polymorphisms or heterozygous causative variants also manifest the TMAU phenotype. In addition, another research hypothesized that the behavioral disturbances showed by patients may be linked to gut microbiota alterations. Our review considers current knowledge about TMAU, clarifying its molecular aspects, the therapeutic approaches used to limit this condition, and the new therapies that are under study.


  • Open Access

    Tau-Marin Mucoadhesive Gel for Prevention and Treatment of Gum Diseases

    by Giuseppe Giannini, Irene Ragusa, Giulia Nerina Nardone, Sara Soldi, Marina Elli, Piera Valenti, Luigi Rosa

    An innovative and stable probiotic-containing mucoadhesive gel (AL0020), integrated with botanical extracts, has been developed to rebalance the dysbiosis associated with periodontal diseases. Tau-Marin gel, prepared with anhydrous ingredients to prevent the replication of bacteria and ensure good stability over time, was tested against some pathogenic bacteria, belonging to the so-called “red complex”, recognized as the most important pathogens in plaque specimens, adherent to the epithelial lining of periodontal pockets. This lipogel was tested in vitro, in a physiological solution (PS) and in a simulated saliva (SS), for up to 8 h, to monitor its ability to release probiotics over time. Probiotics were enumerated through two different techniques, Lacto-Counter Assay (LCA) and Colony Forming Unit (CFU). A detailed physico-chemical profile of AL0020 and its in vitro efficacy in protecting activity against pathogenic bacteria as well as soothing or irritative effect on gingival epithelium were reported. Moreover, a clinical-dermatological trial on 20 volunteers using the product once a day for 30 days was also performed, where the efficacy of the gel in the control of gum disorders was observed.


  • Open Access

    Tau-Marin Mucoadhesive Gel for Prevention and Treatment of Periodontal Diseases

    by Giuseppe Giannini, Irene Ragusa, Giulia Nerina Nardone, Sara Soldi, Marina Elli, Piera Valenti, Luigi Rosa

    : An innovative and stable probiotics-containing mucoadhesive gel (AL0020), integrated with botanical extracts, has been developed to rebalance the dysbiosis associated with periodontal diseases. Tau-Marin gel was tested against some pathogenic bacteria, belonging to the so-called "red complex", recognized as the most important pathogens in plaque specimens, adherent to the epithelial lining of periodontal pockets. A detailed physico-chemical profile of AL0020 and its in vitro efficacy in protecting activity against pathogenic bacteria as well as soothing or irritative effect on gingival epithelium were reported. Moreover, a clinical-dermatological trial on 20 volunteers using the product once a day for 30 days was also performed.


  • Open Access

    Structural Characterization of Human Heat Shock Protein 90 N-Terminal Domain and Its Variants K112R and K112A in Complex with a Potent 1,2,3-Triazole-Based Inhibitor

    by Giusy Tassone, Marco Mazzorana, Stefano Mangani, Elena Petricci, Elena Cini, Giuseppe Giannini, Cecilia Pozzi, Samuele Maramai

    Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that stabilizes client proteins in a folded and functional state. It is composed of two identical and symmetrical subunits and each monomer consists of three domains, the N-terminal (NTD), the middle (MD), and the C-terminal domain (CTD). Since the chaperone activity requires ATP hydrolysis, molecules able to occupy the ATP-binding pocket in the NTD act as Hsp90 inhibitors, leading to client protein degradation and cell death. Therefore, human Hsp90 represents a validated target for developing new anticancer drugs. Since protozoan parasites use their Hsp90 to trigger important transitions between different stages of their life cycle, this protein also represents a profitable target in anti-parasite drug discovery. Nevertheless, the development of molecules able to selectively target the ATP-binding site of protozoan Hsp90 is challenging due to the high homology with the human Hsp90 NTD (hHsp90-NTD). In a previous work, a series of potent Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold was developed. The most promising inhibitor of the series, JMC31, showed potent Hsp90 binding and antiproliferative activity in NCI-H460 cells in the low-nanomolar range. In this work, we present the structural characterization of hHsp90-NTD in complex with JMC31 through X-ray crystallography. In addition, to elucidate the role of residue 112 on the ligand binding and its exploitability for the development of selective inhibitors, we investigated the crystal structures of hHsp90-NTD variants (K112R and K112A) in complex with JMC31.


  • Quinolines and Oxazino-quinoline Derivatives as Small Molecule GLI1 Inhibitors Identified by Virtual Screening

    by Fabrizio Manetti, Luisa Maresca, Enrica Crivaro, Sara Pepe, Elena Cini, Snigdha Singh, Paolo Governa, Samuele Maramai, Giuseppe Giannini, Barbara Stecca, et al.

    A virtual screening approach based on a five-feature pharmacophoric model for negative modulators of GLI1 was applied to databases of commercially available compounds. The resulting quinoline derivatives showed significant ability to reduce the GLI1 protein level and were characterized by submicromolar antiproliferative activity toward human melanoma A375 and medulloblastoma DAOY cell lines. Decoration of the quinoline ring and chemical rigidification to an oxazino-quinoline scaffold allowed us to deduce SAR considerations for future ligand optimization.


  • Open Access

    Probiotics‐Containing Mucoadhesive Gel for Targeting the Dysbiosis Associated with Periodontal Diseases

    by Giuseppe Giannini, Irene Ragusa, Giulia Nerina Nardone, Sara Soldi, Marina Elli, Piera Valenti, Luigi Rosa, Emanuele Marra, Daniela Stoppoloni, Emilio Merlo Pich

    Objective. Periodontitis is a common disorder that leads to the loss of both tooth and personal well‐being, contributing to worsen the risk for metabolic and cardiovascular diseases. Recently, probiotics, characterized by rapid oral dispersion, have been topically used. Here, we present data of a mucoadhesive gel containing probiotics, capable of ensuring a slow release of bacteria to prevent and treat periodontitis. Methods. An original mucoadhesive gel (AL0005) that is anhydrous and of food grade, loaded with the blend of lactobacilli and plants’ dry extracts, has been assayed. Results. The release kinetics of the bacterial mixture in different experimental models in vitro, including simulated saliva or physiological solutions, showed a significant and stable release for 5–8 hours. In one in vivo study of a mouse model of periodontitis, a locally applied mucoadhesive gel enriched with probiotic strains improved significantly the tissue pathology when compared with vehicle‐exposed mice. Conclusions. Together, the results suggest that this mucoadhesive gel can be useful in the normalization of the gum bacterial flora and improvement of the tissue pathology of gum disorders.


  • Open Access

    Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition

    by Claudio Cianferotti, Valentina Faltoni, Elena Cini, Elena Ermini, Francesca Migliorini, Elena Petricci, Maurizio Taddei, Laura Salvini, Gianfranco Battistuzzi, Ferdinando Maria Milazzo, et al.

    Antitumor hydroxamates SAHA and Dacinostat have been linked to cetuximab and trastuzumab through a non-cleavable linker based on the p-mercaptobenzyl alcohol structure. These antibody drug conjugates (ADCs) were able to inhibit HDAC in several tumour cell lines. The cetuximab based ADCs block human lung adenocarcinoma cell proliferation, demonstrating that bioconjugation with antibodies is a suitable approach for targeted therapy based on hydroxamic acid-containing drugs. This work also shows that ADC-based delivery might be used to overcome the classical pharmacokinetic problems of hydroxamic acids.


  • The Control of Heparanase Through the Use of Small Molecules

    by Giuseppe Giannini, Gianfranco Battistuzzi, Silvia Rivara

    Despite the enormous progress made in recent years with antibodies, vaccines, antisense oligonucleotides, etc., the so-called “biological” approaches for tackling the control of various diseases, medicinal chemistry remains a bulwark to refer to for the development of new drugs. Also in the case of heparanase, medicinal chemistry has always been in the forefront to identify new inhibitors, through modification of natural macromolecules, e.g., sulfated polysaccharides like heparin, or of natural compounds isolated from bacteria or plants, or through rational design. In this chapter, the reader will find a detailed description of the most relevant small-molecule heparanase inhibitors reported so far in the scientific literature and in patent applications, with mention to the design strategy and to structure-activity relationships. Starting from heparanase inhibitors of natural origin and the attempts to improve their potency and selectivity, the reader will be guided through the major chemical classes of synthetic inhibitors, with representation of the structure of the most relevant compounds. The last paragraph is dedicated to a brief description of inhibitors that have reached clinical trials, highlighting their structure, mechanism, and improved derivatives.


  • Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents

    by Fabrizio Manetti, Barbara Stecca, Roberta Santini, Luisa Maresca, Giuseppe Giannini, Maurizio Taddei, Elena Petricci

    Starting from known GLI1 inhibitors, a pharmacophore-based virtual screening approach was applied to databases of commercially available compounds with the aim of identifying new GLI1 modulators. As a result, three different chemical scaffolds emerged that were characterized by a significant ability to reduce the transcriptional activity of the endogenous Hedgehog-GLI pathway and GLI1 protein level in murine NIH3T3 cells. They also showed a micromolar antiproliferative activity in human melanoma (A375) and medulloblastoma (DAOY) cell lines, without cytotoxicity in non-neoplastic mammary epithelial cells.